We found that clinicopathological and imaging characteristics of lesions in patients with sMPLA could assist to predict the mutation status of EGFR, TP53 and KRAS, and provide direction for precise treatment strategies for synchronous multiple primary lung adenocarcinoma. This evidence concerns the gene KRAS and lung adenocarcinoma.